Oaktree Acquisition Corp. III Life Sciences Q1 2025 10-Q Filed
Ticker: OACCU · Form: 10-Q · Filed: May 14, 2025 · CIK: 2029769
| Field | Detail |
|---|---|
| Company | Oaktree Acquisition Corp. III Life Sciences (OACCU) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, SPAC, financials, life-sciences
TL;DR
**Oaktree Acquisition Corp. III Life Sciences Q1 2025 10-Q is in. Financials for the period ending March 31, 2025, are now public.**
AI Summary
Oaktree Acquisition Corp. III Life Sciences filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including data on common stock, additional paid-in capital, and retained earnings. The company's principal executive offices are located at 333 South Grand Avenue, Los Angeles, CA.
Why It Matters
This filing provides investors with the latest financial performance and position of Oaktree Acquisition Corp. III Life Sciences, crucial for understanding its current operational status and future prospects.
Risk Assessment
Risk Level: medium — As a Special Purpose Acquisition Company (SPAC), Oaktree Acquisition Corp. III Life Sciences faces inherent risks related to its ability to identify and complete a business combination within its specified timeframe.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the start of the financial quarter being reported.)
- 1231 — Fiscal Year End (Defines the company's annual financial reporting cycle.)
Key Players & Entities
- Oaktree Acquisition Corp. III Life Sciences (company) — Filer of the 10-Q
- 333 South Grand Avenue, 28th Floor, Los Angeles, CA 90071 (location) — Company's business and mailing address
- March 31, 2025 (date) — End of the reporting period
- 20250514 (date) — Filing date of the 10-Q
FAQ
What is the primary business of Oaktree Acquisition Corp. III Life Sciences?
The filing indicates Oaktree Acquisition Corp. III Life Sciences is a blank check company, with SIC code 6770 (Blank Checks).
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 14, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 333 South Grand Avenue, 28th Floor, Los Angeles, CA 90071.
What financial periods are covered by this 10-Q?
This 10-Q covers the period from January 1, 2025, to March 31, 2025.
What are the different classes of shares mentioned in the filing?
The filing mentions Class A Ordinary Shares, Class B Ordinary Shares, Redeemable Class A Ordinary Shares, and Non-Redeemable Class A and B Ordinary Shares.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Oaktree Acquisition Corp. III Life Sciences (OACCU).